Influx HealthtechNSE:INFLUX +2.90%21 ROE % is 22.05% as of Mar. 2026, which is 66% below its 10-year median of 64.64. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 935 Drug Manufacturers companies, Influx Healthtech ranks better than 92.83% on this metric.
The historical rank and industry rank for Influx Healthtech's ROE % or its related term are showing as below:
NSE:INFLUX'
s ROE % Range Over the Past 10 Years
Min: 27.13 Med: 64.64 Max: 99.54
Current: 27.13
During the past 5 years, Influx Healthtech's highest ROE % was 99.54%. The lowest was 27.13%. And the median was 64.64%.
NSE:INFLUX's ROE % is ranked better than 92.83% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs NSE:INFLUX: 27.13
Influx Healthtech (NSE:INFLUX) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Influx Healthtech ROE % Related Terms
Influx Healthtech ROE % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's ROE % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Influx Healthtech (NSE:INFLUX) has a ROE % of 22.05% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Influx Healthtech and its competitors. This is 66% below median its historical median of 64.64. Over the past decade, Influx Healthtech's ROE % has ranged from 27.13 to 99.54. According to the industry distribution chart, Influx Healthtech ranks #67 out of 935 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is Influx Healthtech's ROE % too high?
Influx Healthtech's current ROE % of 22.05% is 66% below median its 10-year median of 64.64. Over the past 10 years, this metric has ranged from a low of 27.13 to a high of 99.54. The Drug Manufacturers industry median ROE % is 6.00. Influx Healthtech's value of 22.05% is 267.5% above this industry median. Based on the distribution chart, Influx Healthtech ranks #67 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #67 out of 935 companies for ROE %. This places Influx Healthtech in the top 7% of its industry — outperforming the majority of peers. The industry median ROE % is 6.00. Influx Healthtech's value of 22.05% is 267.5% above this benchmark. Historically, Influx Healthtech's own ROE % has ranged from 27.13 to 99.54 over the past decade. While the company's 10-year median is 64.64 vs. the industry median of 6.00, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current ROE % of 22.05% is 267.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current ROE % is 22.05%, which is 66% below median its own 10-year median of 64.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current ROE % of 22.05%. The current ROE % is 22.05%, which is 66% below median its 10-year median of 64.64 and 267.5% above the Drug Manufacturers industry median of 6.00. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current ROE % is 22.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 